BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $207,857,177 | -16.8% | 3,053,580 | -0.2% | 2.44% | -10.2% |
| Q2 2023 | $249,758,233 | +11.3% | 3,059,638 | +1.1% | 2.72% | +4.9% |
| Q1 2023 | $224,497,293 | -3.6% | 3,025,978 | +7.6% | 2.59% | -7.6% |
| Q4 2022 | $232,978,149 | +21.8% | 2,811,030 | +317.3% | 2.80% | +16.2% |
| Q3 2022 | $191,308,000 | -15.9% | 673,620 | +2.7% | 2.41% | -11.4% |
| Q2 2022 | $227,371,000 | -20.2% | 655,930 | -0.3% | 2.72% | -5.1% |
| Q1 2022 | $284,924,000 | -15.8% | 657,962 | +0.6% | 2.87% | -8.4% |
| Q4 2021 | $338,244,000 | +5.3% | 653,815 | -1.3% | 3.13% | -2.5% |
| Q3 2021 | $321,092,000 | -2.2% | 662,634 | -9.1% | 3.21% | -0.9% |
| Q2 2021 | $328,166,000 | +11.6% | 728,836 | -5.4% | 3.24% | +5.0% |
| Q1 2021 | $294,099,000 | +9.2% | 770,035 | -9.2% | 3.09% | +3.2% |
| Q4 2020 | $269,308,000 | +27.1% | 848,081 | -0.9% | 2.99% | +13.1% |
| Q3 2020 | $211,904,000 | -11.0% | 855,383 | -5.2% | 2.65% | -14.9% |
| Q2 2020 | $238,180,000 | +22.7% | 901,958 | -11.9% | 3.11% | +9.8% |
| Q1 2020 | $194,161,000 | -11.8% | 1,023,949 | +2.1% | 2.83% | +13.3% |
| Q4 2019 | $220,158,000 | +8.2% | 1,002,952 | -3.6% | 2.50% | +1.7% |
| Q3 2019 | $203,554,000 | -8.6% | 1,040,295 | -2.6% | 2.46% | -7.9% |
| Q2 2019 | $222,698,000 | -2.8% | 1,068,146 | -7.4% | 2.67% | -4.0% |
| Q1 2019 | $229,077,000 | +33.0% | 1,153,750 | -3.1% | 2.78% | +19.7% |
| Q4 2018 | $172,269,000 | -27.9% | 1,190,362 | +1.7% | 2.32% | -16.5% |
| Q3 2018 | $238,987,000 | +25.1% | 1,170,875 | -9.4% | 2.78% | +17.4% |
| Q2 2018 | $191,104,000 | -8.2% | 1,291,677 | -6.3% | 2.37% | -7.8% |
| Q1 2018 | $208,185,000 | +12.0% | 1,378,347 | -3.9% | 2.57% | +19.3% |
| Q4 2017 | $185,847,000 | +6.4% | 1,434,557 | -0.7% | 2.16% | +2.8% |
| Q3 2017 | $174,623,000 | +2.6% | 1,444,480 | -0.3% | 2.10% | +1.8% |
| Q2 2017 | $170,256,000 | +20.5% | 1,448,987 | +4.3% | 2.06% | +18.9% |
| Q1 2017 | $141,278,000 | +0.4% | 1,389,850 | +1.5% | 1.73% | -4.2% |
| Q4 2016 | $140,738,000 | -6.0% | 1,368,650 | +0.1% | 1.81% | -8.4% |
| Q3 2016 | $149,697,000 | -1.8% | 1,367,099 | +1.2% | 1.97% | -4.1% |
| Q2 2016 | $152,382,000 | +23.0% | 1,351,264 | +3.1% | 2.06% | +16.8% |
| Q1 2016 | $123,875,000 | +5.3% | 1,310,574 | +0.3% | 1.76% | -0.1% |
| Q4 2015 | $117,620,000 | -1.7% | 1,306,885 | +1.0% | 1.76% | -5.7% |
| Q3 2015 | $119,599,000 | -11.8% | 1,293,524 | -6.1% | 1.87% | -2.7% |
| Q2 2015 | $135,637,000 | -2.0% | 1,377,442 | -0.2% | 1.92% | +0.9% |
| Q1 2015 | $138,369,000 | +15.6% | 1,379,687 | +6.5% | 1.90% | +14.6% |
| Q4 2014 | $119,697,000 | +17.4% | 1,295,420 | +18.8% | 1.66% | +11.6% |
| Q3 2014 | $101,972,000 | – | 1,090,022 | – | 1.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |